Dr. Kane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1665 Ursula St
F704
Aurora, CO 80045Phone+1 720-848-0300Fax+1 720-848-0360
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 1981 - 1984
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1978 - 1981
University of Miami Leonard M. Miller School of MedicineClass of 1978
Certifications & Licensure
NY State Medical License 1984 - Present
CA State Medical License 1979 - 2025
CO State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate
- Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
- Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck Start of enrollment: 2004 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsImpact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers.Noah Kastelowitz, Megan D. Marsh, Martin D. McCarter, Robert A. Meguid, Narine Wandrey Bhardwaj
Frontiers in Oncology. 2021-03-10 - 6 citationsA Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination ...S. Lindsey Davis, S. Gail Eckhardt, Jennifer R. Diamond, Wells A. Messersmith, Arvind Dasari
The Oncologist. 2018-12-01 - 83 citationsTreatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.Laura D. Locati, Lisa Licitra, Laura Agate, Sai-Hong Ignatius Ou, Andrée Boucher
Cancer. 2014-09-01
Journal Articles
- Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck CancerHilary Somerset, Antonio Jimeno, David Raben, Sana D Karam, Dara L Aisner, Madeleine Kane, Carrie Marshall, Daniel W Bowles, Clinical Cancer Research
Grant Support
- PAUL Calabresis Award In Clinical Oncology ResearchNational Cancer Institute2007–2011
- Protocol Specific ResearchNational Cancer Institute2006–2010
- Data Safety &Monitoring/ Quality AssuranceNational Cancer Institute2006–2010
- Clinical Investigations CoreNational Cancer Institute2006–2010
- Clinical Oncology Research Career Development ProgramNational Cancer Institute2000–2004
- Postgraduate Training In Cancer ResearchNational Cancer Institute1993–1995
- Bombesin-Like Peptide Receptors And Human Lung CancerNational Cancer Institute1992–1995
- Expression Of Gastrin Releasing Peptide ReceptorNational Cancer Institute1991
- Biochemistry Of The Bombesin-Like-Peptide ReceptorNational Cancer Institute1987–1990
- Mechanisms Of Folate Transport In Human CellsNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
